Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 27, 2014. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific director's share transaction and does not contain consolidated financial statements.
Material Changes
The filing details a transaction by Dr. M M Slaoui, a Director of the Company:
- Option Exercise: Exercised options over 26,800 Ordinary Shares on October 27, 2014. These options were granted on December 2, 2004, under the GlaxoSmithKline Share Option Plan at an exercise price of £11.23 per share.
- Share Sale: Sold 26,800 Ordinary Shares on October 27, 2014, at a price of £14.16 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of a director's trading activity.
Investor Verification Points
- Verify the total number of shares held by Dr. M M Slaoui following this transaction.
- Confirm the timing of the transaction relative to any material non-public information.
- Review the terms of the GlaxoSmithKline Share Option Plan regarding the 2004 grant.